On Feb 17, 2026 two analysts maintained a Buy on HIVE Digital Technologies Ltd. (HIVE), making the HIVE analyst rating the main market update of the day. H.C. Wainwright and Roth Capital both left their ratings at Buy, citing undervaluation and optionality in high-performance computing and AI. Neither firm published a new price target in their notes, so the moves focus on strategy rather than a new valuation anchor. The dual maintenance underscores consistent analyst support while leaving near-term price guidance limited for investors tracking HIVE analyst rating changes.
What the HIVE analyst rating maintained to Buy means
A maintained Buy HIVE analyst rating signals continued analyst confidence without a change in conviction. It typically means analysts see structural upside but did not add fresh valuation forecasts. For investors, a maintained Buy is a positive signal, but it is not the same as an upgrade that raises a price target or outlook.
H.C. Wainwright HIVE analyst rating details (Feb 17, 2026)
At 12:36 PM on Feb 17, 2026 H.C. Wainwright maintained a Buy on HIVE, calling the shares “significantly undervalued.” The note did not list a new price target and reported Price Change Since of 0.97% ($0.02) in the feed. Read the report summary source. This maintained rating keeps H.C. Wainwright in the bullish camp on the HIVE analyst rating.
Roth Capital HIVE analyst rating details (Feb 17, 2026)
At 03:18 PM on Feb 17, 2026 Roth Capital also maintained a Buy on HIVE, highlighting optionality in high-performance computing and AI as key upside drivers. The Roth note showed Price Change Since of 0.24% ($0.0) and did not publish a price target in the summary. See the Roth commentary source. Roth’s stance reinforces the HIVE analyst rating continuity.
Impact on HIVE stock and valuation from the HIVE analyst rating
Both maintained Buy calls can support short-term investor sentiment, but absence of new price targets limits directional certainty. HIVE’s market capitalization stands at $504,490,040, which frames analyst views against a mid-cap valuation. With no fresh target, traders may watch fundamentals and crypto cycle signals more than analyst-driven revaluations.
Historical context of HIVE analyst rating coverage
Analyst coverage of HIVE has alternated between bullish Buy calls and cautious Holds as crypto cycles and capacity investments shift momentum. Recent maintained Buy notes continue a trend of analysts emphasizing growth optionality and undervaluation rather than issuing downgrades. Meyka AI rates HIVE with a grade of B+, reflecting S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Investor implications from the HIVE analyst rating maintenance
Investors should interpret the maintained HIVE analyst rating as continued analyst conviction without fresh price guidance, and weigh operational milestones, crypto market swings, and cash position. Because neither note provided a new price target, risk management, position sizing, and watching company updates are prudent. For quick reference see HIVE on Meyka HIVE on Meyka.
Final Thoughts
The Feb 17, 2026 HIVE analyst rating actions by H.C. Wainwright and Roth Capital left both firms at Buy, signaling sustained analyst confidence but no new valuation anchors. That outcome favors sentiment for long-term investors who buy growth optionality and undervaluation, while short-term traders may remain cautious without fresh price targets. The dual maintained Buy highlights bullish thematic drivers such as high-performance computing and AI optionality while underscoring that analysts saw no need to change conviction on the day.
Meyka AI rates HIVE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Investors should combine analyst views, company milestones, and market conditions before acting on any HIVE analyst rating update.
FAQs
What does a maintained Buy mean in the HIVE analyst rating
A maintained Buy in the HIVE analyst rating means analysts keep a positive view but did not raise or lower their recommendation. It signals continued confidence without a fresh valuation or new price target, so investors should watch company updates and market drivers.
Did H.C. Wainwright or Roth Capital give a HIVE price target
Neither H.C. Wainwright nor Roth Capital published a new HIVE price target in the Feb 17, 2026 notes. Both firms maintained a Buy, focusing on undervaluation and AI/HPC optionality instead of issuing updated targets.
How should investors act after this HIVE analyst rating maintenance
Investors should treat the HIVE analyst rating maintenance as supportive but not definitive. Without new price targets, consider position sizing, monitor operational milestones, and track crypto cycle moves before changing exposure.
What does Meyka’s B+ grade mean for the HIVE analyst rating
Meyka’s grade of B+ reflects a mix of relative performance vs the S&P 500, sector momentum, financial growth metrics, and analyst consensus including the recent HIVE analyst rating maintenances. It is an informational gauge, not financial advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
